Navigation Links
Study: Excessive use of antiviral drugs could aid deadly flu
Date:1/7/2009

COLUMBUS, Ohio Influenza's ability to resist the effects of cheap and popular antiviral agents in Asia and Russia should serve as a cautionary tale about U.S. plans to use the antiviral Tamiflu in the event of widespread avian flu infection in humans, scientists say.

Researchers analyzed almost 700 genome sequences of avian influenza strains to document where and when the virus developed resistance to a class of antiviral drugs called adamantanes and how far resistant strains spread. The analysis suggests that widespread antiviral drug use can accelerate the evolution of drug resistance in viruses, and that resistant strains can emerge and spread rapidly.

The results should serve as a warning to those who consider Tamiflu the next great antiviral medication, the researchers say. Stockpiling Tamiflu has become a standard part of many government, business and health organization plans to prepare for a long-feared pandemic flu outbreak, especially in the event that avian flu mutates enough to infect and be easily transmitted among humans.

"We can't necessarily say what we've seen in adamantanes is predictive of what will happen with Tamiflu. But in the larger dynamic, perhaps it serves as a cautionary tale," said Daniel Janies, senior author of the study and an associate professor of biomedical informatics at Ohio State University.

"Fighting infection is an arms race, and if we're not smart about how we use our arms and understand the evolutionary implications, then we will have ongoing and accelerating problems with drug-resistant microorganisms."

Resistance to adamantanes among strains of seasonal influenza spiked in Asia in 2002, and by 2006 the agents were considered virtually worthless worldwide as a treatment for the flu because more than 90 percent of the strains had developed a resistance to the drugs.

With that knowledge, Janies and colleagues analyzed hundreds of avian flu genomes isolated from
'/>"/>

Contact: Daniel Janies
Daniel.Janies@osumc.edu
614-292-1202
Ohio State University
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Study: diabetic neuropathy costs billions per year in lost work time
2. Study: Fountain of youth for your heart?
3. First-ever study: lack of critical lubricant causes wear in joints
4. Mayo Clinic study: Ossurs collars superior in immobilization and reduction of pressure
5. Study: weight-loss tips differ in African-American, mainstream magazines
6. Smithsonian study: Sediment prediction tools off the mark
7. Mouse study: When it comes to living longer, its better to go hungry than go running
8. Geisinger study: Inflammatory disease causes blindness
9. Stanford study: Bioenergy potential of reviving abandoned agricultural land
10. U-M study: Herceptin targets breast cancer stem cells
11. Study: Future snowmelt in West twice as early as expected; threatens ecosystems and water reserves
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2014)... Dec. 4, 2014  Tute Genomics, a leader in ... in Series A1 funding led by UK-based Eurovestech. Peak ... in the investment round. "We are at ... adopts next-generation sequencing and seeks new approaches for the ... Robison , MD MBA, and CEO of Tute Genomics. ...
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/21/2014)... 2014   Atmel® Corporation (NASDAQ: ... touch technology solutions, today launched the industry,s first family ... widest V cc range from 1.7V to 5.5V. ... I 2 C bus communication speeds, and are available ... them ideal for consumer, industrial, computer, and medical applications. ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... Neagh, has lost more than three quarters of its overwintering ... study by Quercus, Northern Ireland,s Centre for Biodiversity and Conservation ... lake for the winter months has dropped from 100,000 to ... research, published in the journal Freshwater Biology , found ...
... Munich, November 13, 2013 - Elsevier, a world-leading provider ... is pleased to announce the launch of the new ... aim of Photoacoustics is to publish original ... field of photoacoustics (optoacoustics) and thermoacoustics. Research in this ...
... , Nov. 13, 2013  Baxter International Inc. today announced ... trial of BAX 855, an investigational extended half-life, recombinant ... trial is aimed at assessing the efficacy of the ... prophylaxis and on-demand treatment schedules, and will also evaluate ...
Cached Biology News:Largest lake in Britain and Ireland has lost three-quarters of winter water birds 2Elsevier launches new open access journal: Photoacoustics 2Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 2Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 3Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 4Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 5Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 6
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
(Date:12/19/2014)... 2014 Charm Sciences is pleased to ... Detection of Aflatoxin M1 in raw commingled milk is ... party validation. The peer reviewed report of the validation ... for Agricultural and Fisheries Research (ILVO-T&V) has been published ... B1, the most toxic aflatoxin and a known carcinogen, ...
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources Group ... grow at a 12 percent compound annual growth rate ... the aging population and the increasing adoption of dental ... will also spur demand for dental biomaterials ... implant and periodontal treatments. Other key findings ...
(Date:12/19/2014)... Ed Bilsky, Ph.D., vice president for ... Excellence in the Neurosciences (CEN), and professor of pharmacology ... as a member of the prestigious Dana Alliance for ... Maine to receive this honor. , The Dana ... the Dana Foundation. Its mission is to advance ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3
... a provider of electronic parts catalogs and related technology ... and record net income for the fiscal year ended July ... million, a 2% increase from revenues of $13.4 million in ... $0.32 per diluted share, from operating income of $1.3 million ...
... and Milwaukee officials on Wednesday announced plans to launch ... network accessible to all residents. , ,The Milwaukee Wireless ... large city in America, built at no cost to ... , ,"This initiative constitutes a multi-million dollar private investment, ...
... is critical to any new medical technology or treatment's ... as determinative. , ,"Coverage" is whether there will ... is how much payment there will be if there ... analyses in their evaluation of new products and, depending ...
Cached Biology Technology:Milwaukee announces citywide wireless initiative 2On track with the FDA -- But what about your coverage and reimbursement strategy? 2On track with the FDA -- But what about your coverage and reimbursement strategy? 3On track with the FDA -- But what about your coverage and reimbursement strategy? 4
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5...
...
RayBio L Series 507: RayBio Label-based Antibody Array I (1 glass slide with 2 subarrays) Class: Antibody Array Products Product Group: Antibody Array...
Rat CXCL7/Thymus Chemokine-1 DuoSet Economy Pack, 45 Plate...
Biology Products: